Cytomegalovirus infection risk with alemtuzumab therapy in hematological malignancies: a retrospective cohort study in the non-transplant setting
Authors:
- 1 July 2024
- journal article
- research article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 65 (11) , 1716-1723
Abstract
Alemtuzumab is a potent lymphocyte-depleting immunotherapy used in solid organ transplan-tation (SOT), that is increasingly being applied in diverse lymphoproliferative disorders (LPDs). However, a significant toxicity limiting expanded usage is cytomegalovirus (CMV) infection, for which standardized preventive strategies exist in SOT but not in LPDs due to a poor understanding of infection risk in this population, with early LPD studies largely limited to stem cell transplantation. Using one of the most diverse arrays of LPDs studied to date, our retrospective cohort study of non-transplant patients receiving alemtuzumab over a ten-year period at a large regional cancer center examines the incidence and clinical profile of infected patients. Among 24 patients, we identified a composite CMV infection rate of 42% with a symptomatic rate of 21%. We also noted significant variations in preventive strategies, which alongside a high infection rate presents an opportunity to improve outcomes through further work in standardization.Keywords
This publication has 27 references indexed in Scilit:
- American Society for Transplantation and Cellular Therapy Series: #3—Prevention of Cytomegalovirus Infection and Disease After Hematopoietic Cell TransplantationTransplantation and Cellular Therapy, 2021
- CMV Infection in Hematopoietic Stem Cell Transplantation: Prevention and Treatment StrategiesCurrent Treatment Options in Infectious Diseases, 2021
- Effect of Preemptive Therapy vs Antiviral Prophylaxis on Cytomegalovirus Disease in Seronegative Liver Transplant Recipients With Seropositive DonorsJAMA, 2020
- Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7)The Lancet Infectious Diseases, 2019
- Who Is the Patient at Risk of CMV Recurrence: A Review of the Current Scientific Evidence with a Focus on Hematopoietic Cell TransplantationInfectious Diseases and Therapy, 2017
- Alemtuzumab and CHOP Chemotherapy for the Treatment of Aggressive Histology Peripheral T Cell Lymphomas: A Multi-Center Phase I StudyClinical Lymphoma Myeloma and Leukemia, 2016
- Risk Factors for Progression from Cytomegalovirus Viremia to Cytomegalovirus Disease after Allogeneic Hematopoietic Stem Cell TransplantationTransplantation and Cellular Therapy, 2012
- Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumabPediatric Blood & Cancer, 2012
- Management of infections in patients with chronic lymphocytic leukemia treated with alemtuzumabAnnals of Hematology, 2008
- Low serum albumin level is associated with cytomegalovirus reactivation in patients with chronic lymphoproliferative diseases treated with alemtuzumab (Campath‐1H)‐based therapiesCancer, 2007